Oxilio Reports Favourable Open-Labelled Clinical Study to Evaluate the Safety and Pharmacokinetic Profile of OXL001 using TRx Technology
Cambridge, UK, 20th June 2023 – TRx Biosciences today announces favourable safety and pharmacokinetic data from a single-part, five-period, sequential, open-labelled Phase 1 study of OXL001, a novel treatment for cancer under development by Oxilio Limited, which leverages TRx’s oral targeted delivery technology. Oxilio has today confirmed that the objectives of the study, conducted at
View Article